FDA recall record

Minivelle recall — FDA D-0336-2021

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal…

Class IIclassification
D-0336-2021official record ID
Apr 28, 2021report date

Recall record at a glance

Official recordD-0336-2021
CategoryDrug Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmNoven Pharmaceuticals Inc.
Report dateApr 28, 2021
Recall initiation dateApr 16, 2021
Quantity12060 cartons
LocationMiami, FL, United States

Official product description

Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. by: Noven Therapeutics, LLC Miami, Florida 33186, NDC 68968-6675-8

Why the product was recalled

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Distribution information

Nationwide within the United States

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugDec 7, 2022

Daytrana recall — FDA D-0071-2023

Defective Delivery System: Recalled lot was found to be out of specification for shear. Shear is an attribute related to the adhesive properties of the transdermal patches.

Class IIFDA: OngoingNoven Pharmaceuticals Inc.
DrugJul 6, 2022

Daytrana recall — FDA D-1169-2022

Defective Delivery System: Customer complaints received for ripping patches and tight release/adhesive transfer.

Class IIFDA: OngoingNoven Pharmaceuticals Inc.
DrugJun 1, 2022

Daytrana recall — FDA D-0889-2022

Defective Delivery System: customer complaints exceeded respective action limits.

Class IIFDA: OngoingNoven Pharmaceuticals Inc.